I am excited to see that a new medication for Parkinson’s Disease is added to the Ontario Drug Benefits formulary. Neupro (rotigotine) is a dopamine agonist formulated as a transdermal patch and is indicated for both early and advanced stages of Parkinson’s disease as well as restless leg syndrome.
April is Parkinson’s Awareness Month. Last year, I wrote a post about common issues faced by individuals affected by Parkinson’s disease. This year, I want to focus on new treatments that are already available or soon coming down the pipeline.
Parkinson’s disease is a neuro-degenerative disorder with progressive loss of dopaminergic neurons in the substantia nigra, the region of the brain that deals with movement, muscle control and balance. Continue reading It’s Parkinson’s Disease but you don’t have to freeze.